Article
MLL3 is a de novo cause of endocrine therapy resistance.
Cancer medicine - 1 Nov 2021
Stauffer Kimberly M, Elion David L, Cook Rebecca S, Stricker Thomas
Abstract excerpt
BACKGROUND: Cancer resequencing studies have revealed epigenetic enzymes as common targets for recurrent mutations. The monomethyltransferase MLL3 is among the most recurrently mutated enzymes in ER+ breast cancer. The H3K4me1 marks created by MLL3 can define enhancers. In ER+ breast cancer, ERα genome-binding sites are primarily distal enhancers. Thus, we hypothesize that mutation of MLL3 will alter the genomic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.